Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis

Fig. 2

Marker levels in highly active antineutrophil cytoplasmic antibody-associated vasculitis before treatment and remission at 6 months after treatment. The enzyme-linked immunosorbent assay titers of markers were measured in paired serum samples (before and at 6 months after the start of treatment) from the 62 patients with antineutrophil cytoplasmic antibody-associated vasculitis (33 microscopic polyangiitis [MPA], 15 granulomatosis with polyangiitis [GPA], 11 eosinophilic granulomatosis with polyangiitis [EGPA], and 3 unclassifiable). Each line connects the data obtained on one patient. Myeloperoxidase (MPO)-ANCA refers to only MPO-ANCA-positive patients (n = 48). CRP C-reactive protein, LRG1 Leucine-rich alpha-2-glycoprotein 1, MMP9 Matrix metalloproteinase 9, TIMP1 Tissue inhibitor of metalloproteinase 1, TKT Transketolase, TNC Tenascin C

Back to article page